Author’s response to reviews

Title: The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis

Authors:
Hiroyuki Kamiya (mlb04194@nifty.com)
Ogee Panlaqui (omp287@yahoo.com.ph)

Version: 2 Date: 05 Feb 2020

Author’s response to reviews:

February 5, 2020
Dr. Bruno Guedes Baldi
Editor of BMC Pulmonary Medicine

Dear Sir,

We revised the previous manuscript entitled “The efficacy of recombinant human soluble thrombomodulin (rhsTM) treatment for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis” considering all of the comments from the Editorial and the reviewers, which you would see in our response.

We would like to ask you to consider it for publication in Journal of BMC Pulmonary Medicine.

We look forward to hearing from you at your earliest convenience.

Sincerely yours,

Hiroyuki Kamiya, MD, PhD. MM
School of Population and Global Health, University of Western Australia, Perth, Australia 6009
Email: mlb04194@nifty.com

Thank you for reviewing our manuscript.
We appreciate all of the reviewers’ comments that were provided to improve the quality of the report.

Reply to reviewer 1

1. Following the comment “We have planned our trial to make some evidence about thrombomodulin for such cases of AE-non-IPF IIPs. So I would like you to add some comments in the discussion section like below; prognosis of AE-non-IPF IIPs and AE-non-IPF ILD is similarly poor to that of AE of IPF. Efficacy of thrombomodulin was suggested for AE-non-IPF IIP cases in the report of Arai et al. Hence, thrombomodulin might be effective for AE-non-IPF IIPs although additional trial might be needed”, additional descriptions were made in the discussion section (the line 6-10 on page 23).